Meeting
2018 ASCO Annual Meeting
Dynamic genomic instability modulation by neoadjuvant therapy in early breast cancer (GEICAM/2006-03_2006-14).
Authors
Emilio Alba
Hospital Clínico Universitario Virgen de la Victoria. GEICAM Spanish Breast Cancer Group., Malaga, Spain
Emilio Alba , Oscar M Rueda , Ana Lluch , Joan Albanell , Suet-Feung Chin , Jose Ignacio Chacon , Lourdes Calvo , Juan De La Haba , Begona Bermejo , Nuria Ribelles , Pedro Sanchez Rovira , Arrate Plazaola , Agusti Barnadas , Eva Maria Carrasco , Jesus Herranz , Massimo Chiesa , Rosalia Caballero , Angela Santonja Climent , Federico Rojo , Carlos Caldas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
GEICAM/2006-03 NCT00432172. GEICAM/2006-14 NCT00841828
Citation
J Clin Oncol 36, 2018 (suppl; abstr 592)
DOI
10.1200/JCO.2018.36.15_suppl.592
Abstract #
592
Poster Bd #
84
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2021 ASCO Annual Meeting
Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.
First Author: Neelima Vidula
Poster
2015 ASCO Annual Meeting
A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).
First Author: Andreas Schneeweiss
Poster
2013 ASCO Annual Meeting
PIK3CA mutations in primary HER2-positive and triple negative breast cancer.
First Author: Sibylle Loibl